Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lung Neoplasms 2Vipoma 1Somatostatinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Temozolomide 4Capecitabine 4Bevacizumab 3Leucovorin 2Fluorouracil 2Everolimus 2temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1batifiban 1aflibercept 1Sunitinib 1Sorafenib 1Sirolimus 1Panobinostat 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Fentanyl 1Etoposide 1Doxorubicin 1Disulfides 1Cytidine Triphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Somatostatinoma × motesanib diphosphate × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡